Dec 5, 2020 · In this study, we evaluated the function of these two enzymes using an EMT-inducible model, the lung cancer A549 cell line. ChIP-seq coupled with transcriptomic analysis showed that EZH2 and KDM6B were able to target and modulate the expression of different genes during EMT.

Oct 7, 2013 · In this study, we assessed a potential epigenetic switch involving histone methylation and demethylation by EZH2 and KDM6A in human MSC differentiation using over-expression, siRNA knockdown, and enzymatic inhibition.

The methyltransferase, Enhancer of Zeste homology 2 (EZH2), trimethylates histone 3 lysine 27 (H3K27me3) on chromatin and this repressive mark is removed by lysine demethylase 6A (KDM6A). Loss of these epigenetic modifiers results in developmental defects. We demonstrate that Ezh2 and Kdm6a transcri …

Feb 7, 2025 · Our study provides preclinical evidence supporting that EZH2 inhibitors may confer therapeutic benefit in KDM6A-deficient ESCC patients. Esophageal carcinoma (EC) is the seventh most common...

Nov 29, 2023 · We identified the induction of lysine demethylase 6B (KDM6B) as the primary epigenetic driver of early immunofibroblast differentiation. In addition, we observed an enrichment for KDM6B gene signature in murine inflammatory fibroblasts and pathogenic stroma of patients with autoimmune diseases.

Jan 6, 2021 · Lysine (K)-specific demethylase 6B (KDM6B), also called jumonji domain-containing protein D3 (JMJD3), could counter the effect of EZH2.

Our study provides preclinical evidence supporting that EZH2 inhibitors may confer therapeutic benefit in KDM6A-deficient ESCC patients. The mutation status of the lysine demethylase 6 A (KDM6A), a gene antagonist to Enhancer of zeste homolog 2 (EZH2), is closely related to the therapeutic efficacy of EZH2 inhibitors in several malignancies.

We showed that lung cancer patients presenting high EZH2 mRNA levels or high KDM6B mRNA levels presented a significantly higher risk of early death (p = 3.4 ×10 −5 and p = 4.8 × 10 −5) compared to patients with lower EZH2 or KDM6B mRNA levels (Figure 1 E–G).

Oct 10, 2020 · Bladder cancer with inactivating KDM6A mutations is potentially targetable through the inhibition of EZH2 (4). To the best of our knowledge, this is the first study to analyze the expression levels of KDM6A, EZH2 and H3K27me3, and …

May 3, 2013 · Inhibition of EZH2 activity and knockdown of Ezh2 gene expression in human MSC resulted in decreased adipogenesis and increased osteogenesis. Conversely, knockdown of Kdm6a gene expression in MSC leads to increased adipogenesis and decreased osteogenesis.